New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
08:01 EDTISIS
theflyonthewall.com: Altair Therapeutics commences Phase IIa AIR645 study
Altair Therapeutics announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010. AIR645 was discovered by Isis Pharmaceuticals (ISIS) and licensed to Altair Therapeutics. :theflyonthewall.com



News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2010
14:18 EDTISIS
theflyonthewall.com: Isis Pharmaceuticals April puts active on elevated volatility into data
Isis Pharmaceuticals is recently up 55c to $11.26. Data is expected in Q1 for Isis Pharmaceuticals mipomersen phase 3 trial study in patients with homozygous familial hypercholesterolemia. ISIS April 10 puts have traded 42 times on transaction volume of 5,060 contracts, above its open interest of 2,286 contracts. February option implied volatility is at 52, March is at 53, April is at 63, and July is at 58; above its 26-week average of 52 according to Track Data, suggesting larger price movement into data. :theflyonthewall.com
07:12 EDTISIS
theflyonthewall.com: Isis Pharmaceuticals shares could recover to mid-teens, says Citigroup

Subscribe for More Information
:theflyonthewall.com